GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kimia Biosciences Ltd (BOM:530313) » Definitions » Interest Coverage

Kimia Biosciences (BOM:530313) Interest Coverage : 0 (At Loss) (As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Kimia Biosciences Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Kimia Biosciences's Operating Income for the six months ended in . 20 was ₹0.00 Mil. Kimia Biosciences's Interest Expense for the six months ended in . 20 was ₹0.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Kimia Biosciences's Interest Coverage or its related term are showing as below:


BOM:530313's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.555
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Kimia Biosciences Interest Coverage Historical Data

The historical data trend for Kimia Biosciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kimia Biosciences Interest Coverage Chart

Kimia Biosciences Annual Data
Trend
Interest Coverage

Kimia Biosciences Semi-Annual Data
Interest Coverage

Competitive Comparison of Kimia Biosciences's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Kimia Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kimia Biosciences's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kimia Biosciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Kimia Biosciences's Interest Coverage falls into.



Kimia Biosciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kimia Biosciences's Interest Coverage for the fiscal year that ended in . 20 is calculated as

Here, for the fiscal year that ended in . 20, Kimia Biosciences's Interest Expense was ₹0.00 Mil. Its Operating Income was ₹0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was ₹0.00 Mil.

Kimia Biosciences had no debt (1).

Kimia Biosciences's Interest Coverage for the quarter that ended in . 20 is calculated as

Here, for the six months ended in . 20, Kimia Biosciences's Interest Expense was ₹0.00 Mil. Its Operating Income was ₹0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was ₹0.00 Mil.

Kimia Biosciences had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Kimia Biosciences  (BOM:530313) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Kimia Biosciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Kimia Biosciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Kimia Biosciences (BOM:530313) Business Description

Traded in Other Exchanges
N/A
Address
Netaji Subhash Place, 974, 9th Floor, Aggarwal Millenium Tower-II, Pitampura, New Delhi, IND, 110 034
Kimia Biosciences Ltd is a company engaged in the manufacturing of bulk drugs. Some of the company's products include Azelnidipine, Deflazacort, Oxaceprol, Seratodast, and Tretinoin among others. Its only operating segment being Pharmaceuticals.

Kimia Biosciences (BOM:530313) Headlines

No Headlines